These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
237 related articles for article (PubMed ID: 37932288)
21. Rapid Elimination of Broadly Neutralizing Antibodies Correlates with Treatment Failure in the Acute Phase of Simian-Human Immunodeficiency Virus Infection. Wu Y; Xue J; Wang C; Li W; Wang L; Chen W; Prabakaran P; Kong D; Jin Y; Hu D; Wang Y; Lei C; Yu D; Tu C; Bardhi A; Sidorov I; Ma L; Goldstein H; Qin C; Lu L; Jiang S; Dimitrov DS; Ying T J Virol; 2019 Oct; 93(20):. PubMed ID: 31375583 [TBL] [Abstract][Full Text] [Related]
22. Development of broadly neutralizing antibodies in HIV-1 infected elite neutralizers. Landais E; Moore PL Retrovirology; 2018 Sep; 15(1):61. PubMed ID: 30185183 [TBL] [Abstract][Full Text] [Related]
23. Diverse recombinant HIV-1 Envs fail to activate B cells expressing the germline B cell receptors of the broadly neutralizing anti-HIV-1 antibodies PG9 and 447-52D. McGuire AT; Glenn JA; Lippy A; Stamatatos L J Virol; 2014 Mar; 88(5):2645-57. PubMed ID: 24352455 [TBL] [Abstract][Full Text] [Related]
24. Reduced Potency and Incomplete Neutralization of Broadly Neutralizing Antibodies against Cell-to-Cell Transmission of HIV-1 with Transmitted Founder Envs. Li H; Zony C; Chen P; Chen BK J Virol; 2017 May; 91(9):. PubMed ID: 28148796 [TBL] [Abstract][Full Text] [Related]
25. Broadly neutralizing antibodies against HIV-1 and concepts for application. Gruell H; Schommers P Curr Opin Virol; 2022 Jun; 54():101211. PubMed ID: 35306354 [TBL] [Abstract][Full Text] [Related]
26. Distinct Immunoglobulin Fc Glycosylation Patterns Are Associated with Disease Nonprogression and Broadly Neutralizing Antibody Responses in Children with HIV Infection. Muenchhoff M; Chung AW; Roider J; Dugast AS; Richardson S; Kløverpris H; Leslie A; Ndung'u T; Moore P; Alter G; Goulder PJR mSphere; 2020 Dec; 5(6):. PubMed ID: 33361123 [TBL] [Abstract][Full Text] [Related]
27. Sensitivity to Broadly Neutralizing Antibodies of Recently Transmitted HIV-1 Clade CRF02_AG Viruses with a Focus on Evolution over Time. Stefic K; Bouvin-Pley M; Essat A; Visdeloup C; Moreau A; Goujard C; Chaix ML; Braibant M; Meyer L; Barin F J Virol; 2019 Jan; 93(2):. PubMed ID: 30404804 [TBL] [Abstract][Full Text] [Related]
30. Potent Induction of Envelope-Specific Antibody Responses by Virus-Like Particle Immunogens Based on HIV-1 Envelopes from Patients with Early Broadly Neutralizing Responses. Beltran-Pavez C; Bontjer I; Gonzalez N; Pernas M; Merino-Mansilla A; Olvera A; Miro JM; Brander C; Alcami J; Sanders RW; Sanchez-Merino V; Yuste E J Virol; 2022 Jan; 96(1):e0134321. PubMed ID: 34668778 [TBL] [Abstract][Full Text] [Related]
31. Broadly neutralizing plasma antibodies effective against autologous circulating viruses in infants with multivariant HIV-1 infection. Mishra N; Sharma S; Dobhal A; Kumar S; Chawla H; Singh R; Makhdoomi MA; Das BK; Lodha R; Kabra SK; Luthra K Nat Commun; 2020 Sep; 11(1):4409. PubMed ID: 32879304 [TBL] [Abstract][Full Text] [Related]
32. Autoreactivity in HIV-1 broadly neutralizing antibodies: implications for their function and induction by vaccination. Verkoczy L; Diaz M Curr Opin HIV AIDS; 2014 May; 9(3):224-34. PubMed ID: 24714565 [TBL] [Abstract][Full Text] [Related]
33. Broadly neutralizing antibodies suppress post-transcytosis HIV-1 infectivity. Lorin V; Malbec M; Eden C; Bruel T; Porrot F; Seaman MS; Schwartz O; Mouquet H Mucosal Immunol; 2017 May; 10(3):814-826. PubMed ID: 27966557 [TBL] [Abstract][Full Text] [Related]
34. Development of screening assays for use of broadly neutralizing antibodies in people with HIV. Lynch RM; Bar KJ Curr Opin HIV AIDS; 2023 Jul; 18(4):171-177. PubMed ID: 37265260 [TBL] [Abstract][Full Text] [Related]
35. Functional Relevance of Improbable Antibody Mutations for HIV Broadly Neutralizing Antibody Development. Wiehe K; Bradley T; Meyerhoff RR; Hart C; Williams WB; Easterhoff D; Faison WJ; Kepler TB; Saunders KO; Alam SM; Bonsignori M; Haynes BF Cell Host Microbe; 2018 Jun; 23(6):759-765.e6. PubMed ID: 29861171 [TBL] [Abstract][Full Text] [Related]
36. Coexistence of potent HIV-1 broadly neutralizing antibodies and antibody-sensitive viruses in a viremic controller. Freund NT; Wang H; Scharf L; Nogueira L; Horwitz JA; Bar-On Y; Golijanin J; Sievers SA; Sok D; Cai H; Cesar Lorenzi JC; Halper-Stromberg A; Toth I; Piechocka-Trocha A; Gristick HB; van Gils MJ; Sanders RW; Wang LX; Seaman MS; Burton DR; Gazumyan A; Walker BD; West AP; Bjorkman PJ; Nussenzweig MC Sci Transl Med; 2017 Jan; 9(373):. PubMed ID: 28100831 [TBL] [Abstract][Full Text] [Related]
37. Humanized Immunoglobulin Mice: Models for HIV Vaccine Testing and Studying the Broadly Neutralizing Antibody Problem. Verkoczy L Adv Immunol; 2017; 134():235-352. PubMed ID: 28413022 [TBL] [Abstract][Full Text] [Related]
38. HIV-1 broadly neutralizing antibody precursor B cells revealed by germline-targeting immunogen. Jardine JG; Kulp DW; Havenar-Daughton C; Sarkar A; Briney B; Sok D; Sesterhenn F; Ereño-Orbea J; Kalyuzhniy O; Deresa I; Hu X; Spencer S; Jones M; Georgeson E; Adachi Y; Kubitz M; deCamp AC; Julien JP; Wilson IA; Burton DR; Crotty S; Schief WR Science; 2016 Mar; 351(6280):1458-63. PubMed ID: 27013733 [TBL] [Abstract][Full Text] [Related]
39. Strategies for eliciting multiple lineages of broadly neutralizing antibodies to HIV by vaccination. Mu Z; Haynes BF; Cain DW Curr Opin Virol; 2021 Dec; 51():172-178. PubMed ID: 34742037 [TBL] [Abstract][Full Text] [Related]